677 related articles for article (PubMed ID: 22905878)
1. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
5. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
Kramer LD; Satlin A; Krauss GL; French J; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Laurenza A; Yang H; Zhu J; Squillacote D
Epilepsia; 2014 Mar; 55(3):423-31. PubMed ID: 24605793
[TBL] [Abstract][Full Text] [Related]
6. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety of perampanel: two randomized dose-escalation studies.
Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D
Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097
[TBL] [Abstract][Full Text] [Related]
9. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
Plosker GL
CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
[TBL] [Abstract][Full Text] [Related]
10. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
11. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
[TBL] [Abstract][Full Text] [Related]
12. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]